Glioma Actively Personalized Vaccine Consortium

Project Information

GAPVAC

Grant agreement ID: 305061

Project closed

Start date 1 November 2012

End date 31 January 2017

Funded under

• Specific Programme "Cooperation": Health

Total cost

€ 7 918 396,00

EU contribution

€ 5 970 436,00

Coordinated by

IMMATICS BIOTECHNOLOGIES GMBH
Germany

• Personalised brain cancer treatment shows potential
  EN